Background: Current guidelines recommend in-hospital venous thromboembolism prophylaxis for many patients and extended/outpatient prophylaxis in high-risk patients undergoing abdomino-pelvic surgery for cancer. Despite these guidelines, extended venous thromboembolism prophylaxis is not used uniformly at all institutions. This study aimed to evaluate the impact of postdischarge prophylaxis practices at two academic medical centers on the rate of postdischarge venous thromboembolism. There was no difference in postdischarge bleeding rates between the groups. Conclusions: Extended prophylaxis likely prevents postdischarge venous thromboembolism after major abdominal surgery without an increased risk of bleeding.
Introduction
Venous thromboembolism (VTE) is an important cause of morbidity and mortality in surgical patients and is largely preventable with risk-appropriate prophylaxis. [1] [2] [3] [4] [5] Perioperative heparin administration has been shown to decrease the incidence of symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), and all-cause mortality. 6 The risk of VTE postsurgery has been demonstrated to persist for up to 12 months, with the highest risk occurring in the first 4-6 weeks. 7 A large proportion of VTE events occur after hospital discharge in surgical patients. [8] [9] [10] Several studies have shown that extended prophylaxis for up to four weeks after discharge significantly reduces the incidence of VTE without increasing bleeding complications or other adverse events in patients who underwent open or laparoscopic abdominal cancer surgery. [11] [12] [13] Consequently, evidence-based guidelines recommend that extended VTE prophylaxis should be considered in high-risk patients undergoing abdomino-pelvic cancer surgery. [14] [15] [16] Despite these guidelines, institutional VTE prophylaxis practices are inconsistent regarding the duration of prophylaxis after surgery. For example, major strides in improving in-hospital VTE prophylaxis for hospitalized surgical patients at Johns Hopkins Hospital (JHH). [17] [18] [19] However, patients undergoing major abdominal surgery for cancer or inflammatory bowel disease (IBD) at JHH were not routinely prescribed postdischarge VTE prophylaxis. Similar surgical patients at the Brigham and Women's Hospital (BWH) had not been routinely given extended prophylaxis until the group began a quality improvement project aimed to reduce postdischarge VTE via prescription of extended, outpatient prophylaxis. 20 Based on previous studies suggesting substantial benefits associated with extended prophylaxis in cancer surgery patients and an increased risk of postoperative VTE in patients with IBD, 12, 21 we hypothesized that patients undergoing major abdominal surgery at BWH would have fewer symptomatic postdischarge VTE than patients from JHH. We examined the prevalence of postoperative VTE among patients undergoing abdominal surgery who were and were not prescribed extended VTE prophylaxis.
Methods
We retrospectively analyzed data obtained from the BWH and the JHH American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) registries. From 1 August 2014 to 30 June 2015 the BWH launched a multidisciplinary quality improvement initiative to reduce postdischarge VTE after surgery. This intervention included prescription and delivery of a four-week outpatient supply of low molecular weight heparin (LMWH) to the bedside of eligible patients prior to discharge. They included patients with a malignancy or IBD who underwent elective abdominal general surgery and had a Caprini score 5 on discharge. They excluded those with a hospital length of stay of over 14 days, history of sepsis or systemic inflammatory response syndrome, ASA class 5, or ventilator dependence and patients with fluctuating renal function or concern for postoperative bleeding. A detailed description of the initiative is published elsewhere. 20 We compared data from the implementation of this project at BWH to a directly comparable cohort of patients at JHH based on specific International Classification of Disease, 9th revision and current procedural terminology codes (Table 1) , as well as the identical exclusion and inclusion criteria for whom the BWH patients were selected to receive extended prophylaxis. 8, 194, 196.6, 196.9, 197.4, 197.5, 197.6, 197.7, 197.8, 198.7, 198 In these institutions patients are risk assessed on admission and high-risk patients are provided with VTE prophylaxis via a computerized order entry system.
Outcomes
The primary outcome was symptomatic postdischarge VTE, defined as the presence of PE (the diagnosis of a new thrombus in a pulmonary artery with evidence of PE on a definitive imaging study) and/or DVT (the diagnosis of a new deep venous thrombosis confirmed by a definitive imaging modality). Secondary outcomes included overall postoperative VTE, in-hospital VTE events, and postdischarge bleeding rates. Outcomes were proactively assessed 30-day postoperatively per ACS-NSQIP protocol and therefore comparable between the two centers. In the ACS-NSQIP, preoperative risk factors, intraoperative factors, and postoperative outcomes are collected by trained research nurses.
Statistical analysis
We compared baseline demographic information and perioperative characteristics of patients who were treated at BWH during the extended prophylaxis intervention with their counterparts at JHH who were not subject to an extended prophylaxis protocol. Categorical variables were compared using Fisher's exact test. T-test and Wilcoxon rank-sum test were used to compare continuous variables when appropriate. We compared the proportion of patients who developed postdischarge VTE between the two groups using a Fisher's exact test. We excluded all patients who had inpatient VTE from this analysis. We compared the proportions of postoperative and inpatient VTE between the two cohorts. A two-tailed p < 0.05 was considered statistically significant. All analyses were performed with Stata version 13.0 (Statacorp) and R version 3.2.4 (R Studio, Boston, Massachusetts). This study was approved by the respective Institutional Review Boards of both institutions.
Results
The study population consisted of 489 patients; 181 patients (37%) from BWH who underwent major abdominal surgery and were eligible for extended prophylaxis under the BWH quality improvement initiative and a similar cohort of 308 (63%) patients at JHH where there was no protocol to prescribe extended prophylaxis. The two groups were similar by age (p = 0.13), gender (p = 0.33), proportion with a history of diabetes (p = 0.14), hypertension (p = 0.85), chronic obstructive pulmonary disease (p = 0.73), bleeding disorder (p = 0.19), and history of cigarette smoking (p = 0.79). They were also similar by preoperative mean creatinine level (p = 0.83) and ASA classification (p = 0.48). In total, 62 (12.7%) had surgery for IBD and 427 (87.3%) for malignancy. There was no difference between the two groups by indication for surgery (p = 0.78) ( Table 2) .
The mean body mass index for patients at BWH was significantly higher than their counterparts at JHH (p = 0.01). Patients at BWH were more likely to have a contaminated (8.3% versus 2.9%) or dirty infected (7.2% versus 2.9%) wound classification compared with patients at JHH (p = 0.01). The median duration of surgery for patients at BWH was significantly shorter than those at JHH (170 min versus 254 min, p < 0.001), and patients at BWH had shorter median length of hospital stay compared with patients at JHH (five days versus seven days, p < 0.001) ( Table 2) . Fourteen patients developed a postoperative VTE including nine with DVT and six with PE. One patient had both DVT and PE. Seven patients developed VTE during the hospital stay and the remaining seven patients suffered VTE postdischarge. Two patients at BWH (1.1%) developed postoperative VTE events, compared with 12 (3.9%) at JHH (p = 0.09). The proportions of postoperative DVT (0.6% versus 2.6%, p = 0.16) and PE (0.6% versus 1.6%, p = 0.42) were statistically similar between patients treated at BWH and JHH. The proportion of inpatient VTE (1.1% versus 1.6%, p = 0.99), DVT (0.6% versus 1.0%, p = 0.99), and PE (0.6% versus 0.7%, p = 0.99) were also similar between the BWH and JHH groups (Table 3; Figure 1 ) While no postdischarge VTEs were observed in patients treated at BWH, seven (2.3%) cases were observed in patients treated at JHH; this was found to be statistically significant (p = 0.0498). The proportions of patients who developed postdischarge DVT (0% versus 1.6%, p = 0.163) and PE (0% versus 1.0%, p= 0.30) were not significantly different between the two groups ( Table 3 ). The median duration to development of VTE postdischarge was 11 days with a range of 3-20 days. All these patients had undergone abdominal surgery for cancer. While one patient from JHH was readmitted for a bleeding complication (0.3%), none of the patients from BWH reported any bleeding episode.
Discussion
This analysis of the ACS-NSQIP data from two academic medical centers found that patients who underwent major abdominal general surgery and received extended VTE prophylaxis for four weeks had no postdischarge VTE compared with seven patients in a comparable group who were not prescribed postdischarge VTE prophylaxis. This study is the first to use ACS-NSQIP to compare postdischarge VTE outcomes between two hospitals with different postdischarge VTE prophylaxis practices after major abdominal surgery. It also offers an opportunity to study the impact of quality improvement initiatives across NSQIP hospitals. Prior to this, several studies including the ENOXOCAN II trial 13 reported on the effectiveness of extended VTE prophylaxis in preventing postdischarge VTE after high-risk abdomino-pelvic oncologic surgery, 22, 23 major orthopedic surgery, 24 major urologic surgery, 25 and in acutely ill medical patients. Our findings add to this evidence supporting the efficacy of extended prophylaxis after abdominal surgery in high-risk patients. Previous studies have established that among patients undergoing general surgery, rates of DVT and fatal PE range from 15 to 30% and from 0.2 to 0.9%, respectively. 27 Similarly, among a cohort of patients who developed VTE in the outpatient setting, close to a quarter of these had recently undergone surgery.
14 These data underscore the significant VTE risk posed by major surgery that persists after hospital discharge. 7 Consequently, postdischarge VTE prophylaxis has been advocated for high-risk patients undergoing cancer-related abdominal and pelvic surgery. 16 In this study, half of all VTE events occurred postdischarge, which compares to 41, 30, and 28% reported for major vascular, oncologic, and colorectal surgical procedures, respectively. [8] [9] [10] In our cohort, none of the patients who developed postdischarge VTE were from BWH which had the postdischarge protocol suggesting that extended prophylaxis may reduce the risk of postdischarge VTE among patients undergoing major abdominal surgery. This study highlights an opportunity for stakeholders to critically evaluate existing data on the role of extended prophylaxis on postdischarge VTE to inform policy on practice. Even though current guidelines recommend extended prophylaxis for highrisk surgical patients, there is little inter-and intrainstitutional consistency in adherence to them. 28, 29 Several reasons have been advanced as barriers to the prescription of extended prophylaxis for high-risk patients. Prominent among these is the perceived risk of bleeding. 9, 12 Although all forms of anticoagulants are associated with some risk of bleeding, published data indicate that extended VTE prophylaxis reduces the risk of postdischarge VTE without an increased risk for bleeding. 16 In our current cohort, no bleeding was reported for the patients who received extended VTE prophylaxis. Another perceived barrier to extended prophylaxis is physician concern regarding patient adherence due to LMWH subcutaneous route of administration. 30, 31 It is important to note, like all other outpatient medications, nonadherence poses a challenge. Although we did not ascertain compliance in the cohort eligible to receive extended prophylaxis, available evidence suggests an acceptable compliance rate when patients are appropriately educated. Patient education may also ensure safe administration. [32] [33] [34] Using oral anticoagulants for extended prophylaxis could help address the issue of nonadherence. 35 Confusion among clinicians as to which patients should be prescribed extended VTE prophylaxis and its cost-effectiveness is an additional barrier to widespread adoption of these established guidelines. For example, the current American College of Chest Physicians guidelines recommend extended prophylaxis for patients undergoing abdominal or pelvic surgery at high risk for VTE without a high risk of major bleeding. 16, 36 The definition of high-risk patient in the postdischarge setting in this recommendation appears nebulous, opening it up for providers to use their discretion which may not be data driven. 37 Any attempts to better and easily define at-risk patients may in part facilitate the widespread adoption of these guidelines further leading to a reduction in VTE events. Current studies have established the cost-effectiveness of extended prophylaxis in at-risk patients; however, some providers may be reluctant to prescribe due to concerns of high cost to patients. 37, 38, 39, 40 This is a credible concern given that the cost for a four-week supply for LMWH used for extended prophylaxis may not be fully covered by all insurance policies. 41 However, Cain et al. 42 reported that regardless of cost, 90% of patients who had undergone major abdominal surgery filled their prescription. Nevertheless, efforts must be made by stakeholders and insurance companies to extend coverage for patients, since the evidence supports the cost-effectiveness of extended VTE prophylaxis for at-risk patients.
Any attempts to circumvent these barriers and ensure adoption of evidence-based practice guidelines in regards to extended VTE prophylaxis would require a collective effort by persons involved in institutional quality improvement and safety initiatives through a systems-based approach. This would require a multidisciplinary team including physicians, nurses, pharmacists, and social workers as demonstrated in previous approaches to ensuring patient safety. 43 A continuous educational intervention interspersed with auditing and feedback would significantly improve provider adherence to evidence-based practice guidelines on extended VTE prophylaxis as evidenced in previous studies. 44, 45 Meanwhile, to improve the quality of care at JHH, we have changed our clinical practice and it is now standard for high-risk patients undergoing major colorectal surgery to receive extended, outpatient VTE prophylaxis.
The NSQIP database has been very useful in assessing outcome measures in surgical patients since its inception. Although it is replete with important postoperative outcomes, it lacks data on some process measures (i.e. VTE prophylaxis) making it difficult to link them to outcomes. To overcome this, we previously linked VTE prophylaxis administration data, a process measure to the NSQIP data at JHH to identify truly preventable VTE events. 46 Also, in this study, we used institutional NSQIP data supplemented with information from each institution on prescription of extended prophylaxis to determine its impact on postdischarge VTE after major abdominal surgery. Our study shows how institutional NSQIP data from different centers could be harnessed to study the impact of process measures on outcomes. To the best of our knowledge this is the first study to use institutional NSQIP data from two centers to directly compare important postoperative process and outcome measures.
We acknowledge the following limitations of this study. First, while BWH had a protocol to prescribe extended prophylaxis for all high-risk abdominal surgery patients, we do not have data on administration for each patient. Similarly, it is possible some patients at JHH could have been prescribed extended prophylaxis although this was not standard practice among providers. We made the assumption that all BWH patients and no JHH patients received extended prophylaxis. If misclassification occurred, it would skew our study results toward the null finding and, in reality, the effect would be even larger. Second, this study compared the prevalence of VTE between JHH and BWH without examining inpatient VTE prophylaxis practices at these centers. Since VTE prophylaxis during the inpatient perioperative period could also contribute to postdischarge VTE, any major difference in inpatient VTE practices between these hospitals could significantly impact our findings. However, we believe such an impact would be minimal since inpatient VTE prophylaxis practices at both institutions are known to be similar. 47, 48 Third, this study includes patients from two tertiary care hospitals whose patient populations may not be comparable to other centers, which may limit the generalizability of our findings. Fourth, we assessed VTE outcomes 30-day postoperation as per the ACS-NSQIP protocol and any events occurring after this period were not included. This is significant because one-third of all VTE events are known to present beyond the first month after surgical procedures.
14 Subsequent studies should focus on including events beyond the 30-day postoperative period. Fifth, we cannot verify or ascertain patient compliance to extended prophylaxis. However, our inability to identify any postdischarge VTE event among the extended prophylaxis group may be an indication of a high compliance rate.
Conclusions
This study establishes an important link between extended VTE prophylaxis and postdischarge VTE in surgical patients, which has been recognized by previous studies. However, this initiative remains sparsely practiced nationally. A concerted effort is required by all stakeholders to ensure adoption of guidelines in support of this initiative. This is a call to surgeons to play a more proactive role in informing high quality care through initiatives geared toward patient safety in both inpatient and outpatient settings. We also demonstrate a collaboration between two health care institutions through data sharing to assess the impact of a quality improvement initiative to change practice. Collaborations like this are needed to drive meaningful changes in practice. 
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